Elanco Acquires Prevtec Microbia
August 1, 2019
Elanco Animal Health acquired Montreal-based Prevtec Microbia, maker of the Coliprotec swine E. coli vaccine line, in an all-cash transaction of CAD $78.5 million (approx. $59.9M USD) plus contingent payments of up to CAD $21.5 million. The deal brings Prevtec's commercial vaccines and R&D pipeline into Elanco to expand its swine portfolio and provide non-antibiotic alternatives for swine producers globally.
- Targets
- Prevtec Microbia Inc.
- Sellers
- Prevtec Microbia shareholders
- Industry
- Biotechnology
- Location
- Quebec, Canada
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Eli Lilly to Acquire Vaccine Company for Up to $1.55 Billion
May 27, 2026
Biotechnology
Vaccine Company, Inc. announced it has entered into a definitive agreement to be acquired by Eli Lilly and Company in a deal valued at up to $1.55 billion, including upfront and milestone-based payments. The acquisition is intended to accelerate development of Vaccine Company’s next-generation in vivo nanoparticle (IVN) vaccine platform, led by a Phase 1-ready Epstein-Barr virus (EBV) vaccine candidate targeting infectious mononucleosis and longer-term EBV-linked diseases.
-
Eli Lilly Acquires Curevo (Shingles) and LimmaTech Biologics (Bacterial Vaccines)
May 26, 2026
Pharmaceuticals
Eli Lilly entered definitive agreements to acquire Curevo Vaccine and LimmaTech Biologics as part of a broader expansion of its infectious disease R&D platform. Lilly will acquire Curevo for up to $1.5 billion and LimmaTech Biologics for up to $780 million, with upfront and additional milestone-based payments.
-
Elanco Acquires AHV International
May 8, 2026
Healthcare Services
Elanco completed its acquisition of AHV International, a Dutch innovator in animal health. Elanco said the deal strengthens its position in the global dairy market by expanding its portfolio for transition cows and improving dairy production, including technologies such as StopLac and Quorum Sensing.
-
Dechra Pharmaceuticals to Acquire Invetx
July 18, 2024
Biotechnology
Dechra Pharmaceuticals Limited has agreed to acquire Boston-based Invetx Inc., a developer of species-specific monoclonal antibody therapeutics for companion animals, for up to $520 million on a cash-free, debt-free basis, subject to customary approvals. The deal gives Dechra access to Invetx's pipeline and half-life extension platform to expand its specialty veterinary biologics capabilities.
-
Merck Animal Health Acquires Elanco’s Aqua Business
February 6, 2024
Healthcare Services
Elanco Animal Health has agreed to sell its aqua business to Merck Animal Health for approximately $1.3 billion in cash. The divestiture includes aqua products and brands, aqua R&D projects, transfer of manufacturing sites in Prince Edward Island (Canada) and Dong Nai (Vietnam), and about 280 commercial and manufacturing employees, with closing expected around mid-year subject to regulatory approvals.
-
Merck Animal Health Acquires Vence
September 22, 2022
AI & Machine Learning
Merck Animal Health (a division of Merck & Co., Inc.) signed a definitive agreement to acquire Vence from its founders and shareholders. The acquisition will expand Merck Animal Health’s animal intelligence and virtual fencing technology portfolio for cattle producers and ranchers, and is expected to close in Q3 2022 subject to customary conditions.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.